FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Business News

BioGaia Signs Major Distribution Agreement With Partner in Japan

06 Dec 2016 --- Through its Japanese subsidiary BioGaia has signed two new exclusive distributor agreements for Japan with Nippon Kabaya Ohayo Holdings Inc. One for sales of finished probiotic supplements with Lactobacillus reuteri and one for use of Lactobacillus reuteri as ingredient in food. Launches are planned to 2017.

Health & Nutrition News

Social Eating Leads to Overeating, Especially Among Men

06 Dec 2016 --- Gorging at a holiday meal or friend's BBQ might have more to do with your ego than the quality of the food -- especially if you're a man. 

Health & Nutrition News

A Handful of Nuts a Day Cuts Risk of Disease

05 Dec 2016 --- A large analysis of current research shows that people who eat at least 20g of nuts a day have a lower risk of heart disease, cancer and other diseases.

Health & Nutrition News

Yo-Yo Dieting Might Cause Extra Weight Gain

05 Dec 2016 --- Repeated dieting may lead to weight gain because the brain interprets the diets as short famines and urges the person to store more fat for future shortages, new research by the universities of Exeter and Bristol suggests.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html